Literature DB >> 3308827

Genetic predisposition to cancer with special reference to mutagen sensitivity.

T C Hsu1.   

Abstract

From studies on cancer genetics, available information suggests the following tentative conclusions: 1. Cancer starts with a genetic change (or changes) from a normal somatic cell, but the changes (mutational events) must be specific in a target tissue cell. In a number of cases, genetic changes can be detected at the chromosome level. 2. Hereditary cancers usually have one genetic lesion already existing prezygotically; therefore only one additional mutational event is required in the homologous gene to complete the process of neoplastic transformation. In nonhereditary neoplasms, both mutations must occur postzygotically. 3. Individuals with high spontaneous mutation rates (monitored by chromosome breakage rates) are more liable to acquire specific genetic lesions than those with low mutation rates; therefore they are at higher risk to develop neoplasms. 4. Individuals with genetic defects in response to damage induced by mutagens (carcinogens) are more liable to accumulate genetic lesions than those who are more resistant; therefore, they are more liable to develop cancers. Mutagen sensitivity or resistance is probably genetic expression of DNA repair capabilities. 5. An effective assay method for sensitivity or resistance to mutagens can be developed to analyze the human population to identify the at-risk fraction.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3308827     DOI: 10.1007/BF02621067

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  64 in total

1.  CHROMOSOMAL BREAKAGE IN A RARE AND PROBABLY GENETICALLY DETERMINED SYNDROME OF MAN.

Authors:  J GERMAN; R ARCHIBALD; D BLOOM
Journal:  Science       Date:  1965-04-23       Impact factor: 47.728

2.  Human breast carcinomas: marker chromosomes involving 1q in seven cases.

Authors:  Q V Cruciger; S Pathak; R Cailleau
Journal:  Cytogenet Cell Genet       Date:  1976

3.  Quinacrine fluorescent karyotypes of human diploid and heteroploid cell lines.

Authors:  O J Miller; D A Miller; P W Allderdice; V G Dev; M S Grewal
Journal:  Cytogenetics       Date:  1971

4.  Retinoblastoma and deletion D (14) syndrome.

Authors:  M G Wilson; J Melnyk; J W Towner
Journal:  J Med Genet       Date:  1969-09       Impact factor: 6.318

5.  Constitutional translocations and predisposition to T- and B-cell malignancies.

Authors:  S Pathak
Journal:  Cytogenet Cell Genet       Date:  1986

6.  Chromosome instability in patients with medullary carcinoma of the thyroid.

Authors:  T C Hsu; S Pathak; N Samaan; R C Hickey
Journal:  JAMA       Date:  1981-11-06       Impact factor: 56.272

7.  Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha.

Authors:  S Ikegami; T Taguchi; M Ohashi; M Oguro; H Nagano; Y Mano
Journal:  Nature       Date:  1978-10-05       Impact factor: 49.962

8.  Variegated translocation mosaicism in human skin fibroblast cultures.

Authors:  H Hoehn; E M Bryant; K Au; T H Norwood; H Boman; G M Martin
Journal:  Cytogenet Cell Genet       Date:  1975

9.  Genetically determined immunodeficiency diseases (GDID) and malignancy: report from the immunodeficiency--cancer registry.

Authors:  B D Spector; G S Perry; J H Kersey
Journal:  Clin Immunol Immunopathol       Date:  1978-09

10.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

View more
  12 in total

1.  Differential bleomycin susceptibility in cultured lymphocytes of fragile X patients and normal individuals.

Authors:  S Y Li; J K Lin
Journal:  Hum Genet       Date:  1990-08       Impact factor: 4.132

2.  Mammography and hereditary breast cancer.

Authors:  H T Lynch; P Watson
Journal:  Breast Cancer Res Treat       Date:  1990-01       Impact factor: 4.872

3.  Cytogenetic characterization of 20 lymphoblastoid lines derived from human individuals differing in bleomycin sensitivity.

Authors:  T C Hsu; E J Shillitoe; L M Cherry; Q Lin; S P Schantz; C Furlong
Journal:  In Vitro Cell Dev Biol       Date:  1990-01

4.  Increased bleomycin-induced chromosome damage in lymphocytes of patients with common variable immunodeficiency indicates an involvement of chromosomal instability in their cancer predisposition.

Authors:  I Vorechovsky; M Munzarova; J Lokaj
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity.

Authors:  Jian Gu; Yuanqing Ye; Margaret R Spitz; Jie Lin; Lambertus A Kiemeney; Jingliang Xing; Michelle A T Hildebrandt; Waun Ki Hong; Christopher I Amos; Xifeng Wu
Journal:  Hum Mol Genet       Date:  2010-11-24       Impact factor: 6.150

Review 6.  Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis.

Authors:  V A Papadimitrakopoulou; D M Shin; W K Hong
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

Review 7.  Biological staging of head and neck cancer and its role in developing effective treatment strategies.

Authors:  W M Lydiatt; S P Schantz
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

8.  Increased numbers of spontaneous micronuclei in blood lymphocytes and cultures fibroblasts of individuals with familial cutaneous malignant melanoma.

Authors:  M Weichenthal; M Roser; U Ehlert; S Frenzer; E Breitbart; H W Rüdiger
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

9.  Complementation of a DNA repair deficiency in six human tumor cell lines by chromosome 11.

Authors:  R Parshad; F M Price; M Oshimura; J C Barrett; H Satoh; B E Weissman; E J Stanbridge; K K Sanford
Journal:  Hum Genet       Date:  1992-03       Impact factor: 4.132

10.  Expression of fragile sites in childhood acute lymphoblastic leukemia patients and normal controls.

Authors:  P N Rao; N A Heerema; C G Palmer
Journal:  Hum Genet       Date:  1988-08       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.